Asosiy kontentga oʻtish
Maqola

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

Alejandra LeivasDepartment of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainAntonio ValeriDepartment of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainLaura CórdobaH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainAlmudena García-OrtizH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainAlejandra Ortiz-RuizH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainLaura Sánchez-VegaH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainOsvaldo Graña‐CastroBioinformatics Group, Spanish National Cancer Research Centre, Madrid, SpainLucía FernándezH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainGonzalo Carreño‐TarragonaDepartment of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainManuel Pérez‐MartínezConfocal Microscopy Unit, Spanish National Cancer Research Centre, Madrid, SpainDiego Megı́asConfocal Microscopy Unit, Spanish National Cancer Research Centre, Madrid, SpainMaría Liz PacielloDepartment of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainJosé María Sánchez‐PinaDepartment of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainAntonio Pérez‐MartínezDepartment of Pediatrics, Hospital Universitario La Paz, Madrid, SpainDean A. LeeCellular Therapy and Cancer Immunology Program, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USADaniel J. PowellDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USAPaula Rı́oCentro de Investigaciones Energéticas, Medioambientales y TecnológicasJoaquín Martínez‐LópezH12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. [email protected]
2021en
ABI

Annotatsiya

Abstract CAR-T-cell therapy against MM currently shows promising results, but usually with serious toxicities. CAR-NK cells may exert less toxicity when redirected against resistant myeloma cells. CARs can be designed through the use of receptors, such as NKG2D, which recognizes a wide range of ligands to provide broad target specificity. Here, we test this approach by analyzing the antitumor activity of activated and expanded NK cells (NKAE) and CD45RA − T cells from MM patients that were engineered to express an NKG2D-based CAR. NKAE cells were cultured with irradiated Clone9.mbIL21 cells. Then, cells were transduced with an NKG2D-4-1BB-CD3z-CAR. CAR-NKAE cells exhibited no evidence of genetic abnormalities. Although memory T cells were more stably transduced, CAR-NKAE cells exhibited greater in vitro cytotoxicity against MM cells, while showing minimal activity against healthy cells. In vivo, CAR-NKAE cells mediated highly efficient abrogation of MM growth, and 25% of the treated mice remained disease free. Overall, these results demonstrate that it is feasible to modify autologous NKAE cells from MM patients to safely express a NKG2D-CAR. Additionally, autologous CAR-NKAE cells display enhanced antimyeloma activity demonstrating that they could be an effective strategy against MM supporting the development of NKG2D-CAR-NK-cell therapy for MM.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba